Adragasib: A Targeted Therapy for BRAF-Mutated Melanoma
Adragasib (also known as dabrafenib) is a targeted therapy medication used primarily to treat metastatic melanoma, a type of skin cancer. It works by inhibiting the growth of cancer cells that have a specific mutation in the BRAF gene.
- Uses of Adragasib:
Metastatic Melanoma: Adragasib is approved to treat patients with advanced or metastatic melanoma that has a BRAF mutation. - Combination Therapy: It is often used in combination with other targeted therapies or chemotherapy agents to improve treatment outcomes.